Loading...

Karen Kelly

TitleProf
InstitutionUniversity of California Davis
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. McGee HM, Daly ME, Azghadi S, Stewart SL, Oesterich L, Schlom J, Donahue R, Schoenfeld JD, Chen Q, Rao S, Fragoso RC, Valicenti RK, Canter RJ, Maverakis EM, Murphy WJ, Kelly K, Monjazeb AM. Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys. 2018 Apr 22. PMID: 29891204.
      View in: PubMed
    2. Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N, Mehnert JM, Loos AH, Koch H, Speit I, Gulley JL. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer. 2018 May 01; 124(9):2010-2017. PMID: 29469949.
      View in: PubMed
    3. David EA, Andersen SW, Beckett LA, Melnikow J, Kelly K, Cooke DT, Brown LM, Canter RJ. A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients. Ann Thorac Surg. 2017 Nov; 104(5):1665-1672. PMID: 28964421.
      View in: PubMed
    4. David EA, Clark JM, Cooke DT, Melnikow J, Kelly K, Canter RJ. The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 Nov; 12(11):1636-1645. PMID: 28843357.
      View in: PubMed
    5. Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol. 2017 Sep 01; 35(25):2885-2892. PMID: 28493811.
      View in: PubMed
    6. Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J Clin Oncol. 2017 Jul 01; 35(19):2117-2124. PMID: 28375787.
      View in: PubMed
    7. Tam K, Daly M, Kelly K. Treatment of Locally Advanced Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am. 2017 02; 31(1):45-57. PMID: 27912833.
      View in: PubMed
    8. David EA, Daly ME, Li CS, Chiu CL, Cooke DT, Brown LM, Melnikow J, Kelly K, Canter RJ. Increasing Rates of No Treatment in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Propensity-Matched Analysis. J Thorac Oncol. 2017 03; 12(3):437-445. PMID: 28109804.
      View in: PubMed
    9. Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara PN. Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):1-4. PMID: 28082049.
      View in: PubMed
    10. Lara MS, Holland WS, Chinn D, Burich RA, Lara PN, Gandara DR, Kelly K, Mack PC. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 05; 18(3):281-285. PMID: 28038979.
      View in: PubMed
    11. Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM, Blumenschein G. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 03; 12(3):556-566. PMID: 27876675.
      View in: PubMed
    12. Taylor SL, Ruhaak LR, Weiss RH, Kelly K, Kim K. Multivariate two-part statistics for analysis of correlated mass spectrometry data from multiple biological specimens. Bioinformatics. 2017 01 01; 33(1):17-25. PMID: 27592710.
      View in: PubMed
    13. Fahrmann JF, Grapov D, DeFelice BC, Taylor S, Kim K, Kelly K, Wikoff WR, Pass H, Rom WN, Fiehn O, Miyamoto S. Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer. Cancer Biomark. 2016 Mar 11; 16(4):609-17. PMID: 27002763.
      View in: PubMed
    14. Jensen AE, Palombo LJ, Niederberger B, Turcotte LP, Kelly K. Exercise training with blood flow restriction has little effect on muscular strength and does not change IGF-1 in fit military warfighters. Growth Horm IGF Res. 2016 Apr; 27:33-40. PMID: 26922387.
      View in: PubMed
    15. Daly ME, Monjazeb AM, Kelly K. Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1685-93. PMID: 26484629.
      View in: PubMed
    16. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer. 2016 Mar; 17(2):113-8.e1-2. PMID: 26498504.
      View in: PubMed
    17. Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski P, Wang J, Foley MA, Horan JD, Shepherd FA. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2015 Dec 01; 33(34):4007-14. PMID: 26324372.
      View in: PubMed
    18. Fahrmann JF, Kim K, DeFelice BC, Taylor SL, Gandara DR, Yoneda KY, Cooke DT, Fiehn O, Kelly K, Miyamoto S. Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1716-23. PMID: 26282632; PMCID: PMC4633344 [Available on 11/01/16].
    19. Mall C, Sckisel GD, Proia DA, Mirsoian A, Grossenbacher SK, Pai CS, Chen M, Monjazeb AM, Kelly K, Blazar BR, Murphy WJ. Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology. 2016 Feb; 5(2):e1075114. PMID: 27057446.
      View in: PubMed
    20. Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6. PMID: 26106072; PMCID: PMC4592395 [Available on 10/01/16].
    21. Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara DR, Pan CX, Lara PN. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2480-6. PMID: 25739672; PMCID: PMC4452427.
    22. Wikoff WR, Grapov D, Fahrmann JF, DeFelice B, Rom WN, Pass HI, Kim K, Nguyen U, Taylor SL, Gandara DR, Kelly K, Fiehn O, Miyamoto S. Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma. Cancer Prev Res (Phila). 2015 May; 8(5):410-8. PMID: 25657018; PMCID: PMC4618700.
    23. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol. 2015 Jan; 10(1):110-5. PMID: 25490004; PMCID: PMC4320001.
    24. Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014 Aug 10; 32(23):2463-70. PMID: 25002722; PMCID: PMC4121504.
    25. Chen MS, Lara PN, Dang JH, Paterniti DA, Kelly K. Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials. Cancer. 2014 Apr 01; 120 Suppl 7:1091-6. PMID: 24643646; PMCID: PMC3980490.
    26. Wakelee H, Kelly K, Edelman MJ. 50 Years of progress in the systemic therapy of non-small cell lung cancer. Am Soc Clin Oncol Educ Book. 2014; 177-89. PMID: 24857075.
      View in: PubMed
    27. Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2013 Dec; 8(12):1519-28. PMID: 24189513; PMCID: PMC4072123.
    28. Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014 Jan; 15(1):1-6. PMID: 24176733; PMCID: PMC4586161.
    29. Kelly K, Chansky K, Mack PC, Lara PN, Hirsch FR, Franklin WA, Wozniak AJ, Edelman MJ, Williamson SK, Gandara DR. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer. 2013 Nov; 14(6):627-35. PMID: 23910067; PMCID: PMC4122504.
    30. Ruhaak LR, Taylor SL, Miyamoto S, Kelly K, Leiserowitz GS, Gandara D, Lebrilla CB, Kim K. Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Anal Bioanal Chem. 2013 May; 405(14):4953-8. PMID: 23525540; PMCID: PMC3640767.
    31. Gandara DR, Li T, Lara PN, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer. 2012 Sep; 13(5):321-5. PMID: 22677432; PMCID: PMC4049356.
    32. Kelly K, Azzoli CG, Zatloukal P, Albert I, Jiang PY, Bodkin D, Pereira JR, Juhász E, Iannotti NO, Weems G, Koutsoukos T, Patel JD. Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy. J Thorac Oncol. 2012 Jun; 7(6):1041-8. PMID: 22534814.
      View in: PubMed
    33. Ruhaak LR, Miyamoto S, Kelly K, Lebrilla CB. N-Glycan profiling of dried blood spots. Anal Chem. 2012 Jan 03; 84(1):396-402. PMID: 22128873; PMCID: PMC3259271.
    34. Kelly K, Abbott MJ, Turcotte LP. Short-term AMP-regulated protein kinase activation enhances insulin-sensitive fatty acid uptake and increases the effects of insulin on fatty acid oxidation in L6 muscle cells. Exp Biol Med (Maywood). 2010 Apr; 235(4):514-21. PMID: 20407084.
      View in: PubMed
    35. Kelly K, Sung CK, Abbott MJ, Turcotte LP. Phosphatidylinositol 3-kinase-dependent insulin regulation of long-chain fatty acid (LCFA) metabolism in L6 muscle cells: involvement of atypical protein kinase C-zeta in LCFA uptake but not oxidation. J Endocrinol. 2008 Aug; 198(2):375-84. PMID: 18480382.
      View in: PubMed
    36. Lara PN, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol. 2008 Jan 20; 26(3):463-7. PMID: 18202421.
      View in: PubMed
    37. Gandara DR, Chansky K, Albain KS, Gaspar LE, Lara PN, Kelly K, Crowley J, Livingston R. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer. 2006 Sep; 8(2):116-21. PMID: 17026812.
      View in: PubMed
    38. Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara PN, Mack P, Gumerlock PH, Crowley JJ. Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer. 2005 Dec; 7 Suppl 3:S93-7. PMID: 16384543.
      View in: PubMed